Treating Pediatric Myocarditis with High Dose Steroids and Immunoglobulin

Area of Science:

• Pediatric Cardiology
• Immunology
• Critical Care Medicine

Background:

• Myocarditis treatment varies significantly across pediatric centers.
• High-dose steroids and IVIG are used, but outcomes data are limited.

Purpose of the Study:

• To evaluate the safety and efficacy of high-dose steroids combined with IVIG in treating pediatric myocarditis.
• To assess patient outcomes, including survival, cardiac function recovery, and adverse events.

Main Methods:

• Retrospective study of 40 children (<21 years) with myocarditis treated with high-dose steroids and IVIG (Jan 2004-Apr 2021).
• Diagnosis confirmed by endomyocardial biopsy, cardiac MRI (CMR), or clinical criteria.
• Data collected on ejection fraction (EF), treatment duration, IVIG dose, and clinical outcomes.

Main Results:

• 70% of patients diagnosed clinically, 12.5% by CMR, 17.5% by biopsy.
• Median EF at diagnosis was 35%; 70% regained normal function by 3 months.
• 92.5% transplant-free survival with no serious bacterial infections; 25% required mechanical support.

Conclusions:

• High-dose steroids and IVIG appear safe for acute pediatric myocarditis, with minimal infections.
• This combination therapy demonstrates excellent recovery of ventricular function and high survival rates.
• Prospective studies are warranted to compare this regimen against alternative myocarditis treatments.